Bristol-Myers Squibb (NYSE:BMY) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) in a report released on Thursday. The brokerage set a “strong-buy” rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on BMY. Jefferies Financial Group started coverage on Bristol-Myers Squibb in a research note on Monday, March 6th. They issued a “hold” rating and a $62.00 price objective on the stock. Barclays lowered their target price on Bristol-Myers Squibb from $66.00 to $65.00 in a research note on Monday, May 1st. Credit Suisse Group lowered their target price on Bristol-Myers Squibb from $78.00 to $72.00 in a research note on Friday, April 28th. Bank of America increased their target price on Bristol-Myers Squibb from $82.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, April 21st. Finally, Morgan Stanley increased their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “underweight” rating in a research note on Friday, February 3rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Moderate Buy” and an average price target of $79.43.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $66.53 on Thursday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 1.10. The stock’s 50 day moving average price is $68.43 and its two-hundred day moving average price is $72.29. The firm has a market capitalization of $139.77 billion, a price-to-earnings ratio of 19.40, a P/E/G ratio of 1.39 and a beta of 0.44. Bristol-Myers Squibb has a 12-month low of $65.28 and a 12-month high of $81.43.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last released its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.07. The firm had revenue of $11.34 billion for the quarter, compared to analyst estimates of $11.50 billion. Bristol-Myers Squibb had a return on equity of 51.75% and a net margin of 15.95%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.96 earnings per share. On average, analysts anticipate that Bristol-Myers Squibb will post 8.06 earnings per share for the current year.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Rupert Vessey sold 50,385 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $67.06, for a total transaction of $3,378,818.10. Following the sale, the executive vice president now directly owns 47,751 shares of the company’s stock, valued at approximately $3,202,182.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.08% of the stock is owned by insiders.

Institutional Trading of Bristol-Myers Squibb

Large investors have recently bought and sold shares of the company. Boston Financial Mangement LLC boosted its position in shares of Bristol-Myers Squibb by 0.9% in the third quarter. Boston Financial Mangement LLC now owns 15,468 shares of the biopharmaceutical company’s stock worth $1,100,000 after acquiring an additional 133 shares during the last quarter. Accredited Investors Inc. boosted its position in shares of Bristol-Myers Squibb by 0.9% in the third quarter. Accredited Investors Inc. now owns 15,461 shares of the biopharmaceutical company’s stock worth $1,099,000 after acquiring an additional 134 shares during the last quarter. Lincoln National Corp boosted its position in shares of Bristol-Myers Squibb by 0.4% in the third quarter. Lincoln National Corp now owns 36,282 shares of the biopharmaceutical company’s stock worth $2,579,000 after acquiring an additional 140 shares during the last quarter. CWA Asset Management Group LLC boosted its position in shares of Bristol-Myers Squibb by 1.4% in the third quarter. CWA Asset Management Group LLC now owns 10,053 shares of the biopharmaceutical company’s stock worth $715,000 after acquiring an additional 140 shares during the last quarter. Finally, Elmwood Wealth Management Inc. boosted its position in shares of Bristol-Myers Squibb by 1.0% in the third quarter. Elmwood Wealth Management Inc. now owns 13,686 shares of the biopharmaceutical company’s stock worth $973,000 after acquiring an additional 140 shares during the last quarter. 75.51% of the stock is owned by institutional investors.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.